Hervolution Therapeutics

We’re presenting at #SITC2025! Stop by Poster #646 to learn how we’re targeting the dark genome in solid tumors with IPT001. #Immunotherapy #CancerResearch #Oncology

Heading to Berlin for #ESMO2025 – looking forward to engaging with #oncology leaders and exploring the latest in cancer research and treatment innovation. Get in touch if you’ll be attending! #CancerResearch #MedicalOncology

This week at the Aging Research & Drug Discovery Meeting, CSO Peter Holst presented a snapshot of HERVolution and our HERV-targeting approach to developing immunotherapies for age-related diseases like #cancer and #metabolic disorders. Learn more: hervolutiontx.com

HERVolution CSO Peter Johannes Holst is heading to Amsterdam for the 8th Annual International Neoantigen Summit, June 24-26th. Learn more about our approach: hervolutiontx.com We hope to see you there! #Cancer #HERV

CEO Robert Coleman and CSO Peter Johannes Holst are attending the Inaugural Dark Genome Target Discovery & Development Summit, held this week in Boston. Learn more: hervolutiontx.com See you at the summit! #Cancer #HERV #DarkGenome

NEWS: Tine Gaziel, MD, PhD has been appointed as CMO. Dr. Gaziel will lead our clinical pipeline, including lead assets, IPT-001 and IPT-002—HERV-targeting immune therapies with potential to address diseases of aging like #cancer + #diabetes. Learn more: hervolutiontx.com/news/hervoluti…

Next week, our Director of Preclinical R&D Lasse Neukirch, PhD, will present data highlighting our platform’s ability to break immune tolerance against #DarkGenome antigens for therapeutic targeting of #SolidTumors at the Tumour Models Summit Nordics in Stockholm, Sweden!

Proud to announce our $11.7M Series A financing. Led by @SerumInstIndia + supported by @EU_EISMEA, funding will enable us to develop immunotherapies to target HERVs from the #DarkGenome to treat #cancer and #DiseasesOfAging. hervolutiontx.com/news/dark-geno…

Our latest article, "Cancer Vaccines: Recent Insights and Future Directions," has been published in the International Journal of Molecular Sciences as part of their Special Issue "Update on Immunotherapies for Cancer. Read it here: mdpi.com/1422-0067/25/2… #IJMS #CancerVaccine

CEO J. Robert Coleman, PhD, and CSO Peter Johannes Holst, MD, PhD, head to New York City this week to convene with global experts and researchers at the 3rd Annual Dark Genome Symposium, held November 20th-21st. More: thedarkgenomesymposium.com/2024 #DarkGenomeSymposium #DarkGenome

We're thrilled to welcome #ERV expert Enzo Tramontano to UCPH on March 8. His expertise in retroviruses will provide valuable insights and contribute to our understanding of this fascinating & emerging field. #JoinTheHervolution #HealthcareOfTomorrow

Our founder & CSO, Peter Holst, will be presenting why HERVs are emerging as a cancer target at the Biologics World Nordics Conference in CPH. #JoinTheHervolution #HealthcareOfTomorrow

At #JPM2024. Looking forward to valuable insights and meaningful collaborations with industry experts. Together, we're forging the path towards groundbreaking healthcare solutions. #JoinTheHervolution #HealthcareOfTomorrow

Welcome Robert Coleman - our new CEO! Robert's proven ability to navigate from early-stage innovation to clinical advancement will undoubtedly play a pivotal role in realizing the full potential of @Hervolutiontx 's pioneering #immunotherapies. Read more: hervolutiontx.com/2023/12/19/j-r…

Looking forward to attending the #LSXInvestival Showcase and the #LSXEuropeanLifestarsAwards evening next week. Get in touch if you'd like to meet the team and find out about @HERVOLUTION’s first-in-class immunotherapies targeting #HERV tumour antigens

Our CSO, Dr Peter Holst, is presenting data at the SITC on 3rd November detailing our proprietary approach to breaking human immune system tolerance to human endogenous retroviral proteins #HERVs and using anti-HERV immunity to fight #cancer. #immunotherapy #sitc2023 @sitcancer

We are thrilled to have been shortlisted as a finalist for Seed Finance Raise of the Year at the LSX European Lifestars Awards. Best of luck to all the finalists! #LSXEuropeanLifestarsAwards #HERV #SeedFinancing

@HERVOLUTION is honoured to welcome Professor Robert Langer, co-founder of Moderna and MIT Professor, as Chair of its Scientific Advisory Board. Read more here: hervolutiontx.com/2023/09/13/her… #HERVs #immunotherapy

Our recent rebrand to HERVOLUTION Therapeutics reflects our vision of developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs). Visit our new website to find out more: hervolutiontx.com #HERVOLUTION #HERVs #immunotherapy

Exciting new research by Skandorff et al., Daradoumis et al., and Ng et al. reveal the importance of endogenous #retrovirus immunity in tumor immunity. These findings have significant implications for our understanding of immune responses in #cancer. inprother.com/2023/06/09/new…